

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	09/802,445
Filing Date	March 9, 2001
First Named Inventor	Gary VAN NEST
Art Unit	1648
Examiner Name	Z. Lucas
Attorney Docket Number	377882001300

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
32	1.	US-2002/0028784-A1	03-07-2002	Nest	
32	2.	US-2001/0046967-A1	11-29-2001	Van Nest	
32	3.	US-2002/0098199-A1	07-25-2002	Van Nest et al.	
32	4.	US-2003/0050263-A1	03-13-2003	Krieg et al.	
32	5.	US-2003/0216340-A1	11-20-2003	Van Nest et al.	
32	6.	US-2004/0009942-A1	01-15-2004	Van Nest	
32	7.	US-2004/0030118-A1	02-12-2004	Wagner et al.	
32	8.	US-2005/0059626-A1	03-17-2005	Van Nest et al.	
32	9.	US-6,339,068-B1	01-15-2002	Krieg et al.	
32	10.	US-6,406,705-B1	06-18-2002	Davis et al.	
32	11.	US-6,498,148-B1	12-24-2002	Raz	
32	12.	US-6,534,062-B2	03-18-2003	Raz et al.	
32	13.	US-6,552,006-B2	04-22-2003	Raz et al.	
32	14.	US-6,613,751-B2	09-02-2003	Raz et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
32	15.	WO-01/68117-A2,A3	09-20-2001	Dynavax Technologies Corporation		
	16.	WO-01/76642-A1	10-18-2001	The Regents of the University of California		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
32	17.	Current Drugs Ltd. (February 24, 2003). "Lilly and 3M Suspend Resiquimod Trials," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...</a> >, last visited on October 13, 2005, 1 page.	
32	18.	Current Drugs Ltd. (February 24, 2003). "Preliminary Data from Recently Completed Clinical Trials of Resiquimod Suggest Dosing Used in Studies will not Achieve Adequate Efficacy," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...</a> >, last visited on October 13, 2005, 1 page.	
32	19.	Guerrero-Plata, A. et al. (August 2005). "Activity and Regulation of Alpha Interferon in Respiratory Syncytial Virus and Human Metapneumovirus Experimental Infections," <i>Journal of Virology</i> 79(16):10190-10199.	
32	20.	Huang, Z. et al. (August 2003). "Newcastle Disease Virus V Protein is Associated with Viral Pathogenesis and Functions as an Alpha Interferon Antagonist," <i>Journal of Virology</i> 77(16):8676-8685.	


Examiner  
Signature

pa-1026218

Date  
Considered

11/9/06





ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/802,445		
		Filing Date	March 9, 2001		
		First Named Inventor	Gary VAN NEST		
		Art Unit	1648		
		Examiner Name	Z. Lucas		
Sheet	2	of	2	Attorney Docket Number	377882001300

32	21.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07839 filed March 12, 2001, 6 pages.	
32	22.	International Search Report mailed June 18, 2002 for PCT Application No. PCT/US01/07841 filed March 12, 2001, 6 pages.	
32	23.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07931 filed March 12, 2001, 7 pages.	
32	24.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07842 filed March 12, 2001, 6 pages.	
32	25.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07840 filed March 12, 2001, 6 pages.	
32	26.	Jones, M. et al. (May 2005). "Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression," <i>Journal of Virology</i> 79(9):5414-5420.	
32	27.	Lin, R.-J. et al. (September 2004). "Blocking of the Alpha Interferon-Induced Jak-Stat Signaling Pathway by Japanese Encephalitis Virus Infection," <i>Journal of Virology</i> 78(17):9285-9294.	
32	28.	Pantelic, L. et al. (February 2005). "Differential Induction of Antiviral Effects Against West Nile Virus in Primary Mouse Macrophages Derived for Flavivirus-Susceptible and Congenic Resistant Mice by Alpha/Beta Interferon and Poly(I-C)," <i>Journal of Virology</i> 79(3):1753-1764.	
32	29.	Porter, K.R. et al. (1998). "Protective Efficacy of a Dengue 2 DNA Vaccine in Mice and the Effect of CpG Immuno-stimulatory Motifs on Antibody Responses," <i>Arch. Virol.</i> 143:997-1003.	
32	30.	Rauthan, M. et al. (2004). "Oral Immunization of Mice with Japanese Encephalitis Virus Envelope Protein Synthesized in <i>Escherichia coli</i> Induces Anti-viral Antibodies," <i>Microbes and Infection</i> 6:1305-1311.	
32	31.	Seo, S.H. et al. (September 2002). "Lethal H5N1 Influenza Viruses Escape Host Anti-viral Cytokine Responses," <i>Nature Medicine</i> 8(9):950-954.	
32	32.	Silverman, E. et al. (2003). "Immunostimulatory DNA for Asthma," <i>Am. J. Respir. Cell Mol. Biol.</i> 28:645-647.	
32	33.	Smith, V.P. et al. (February 2002). "Inhibition of Interferons by Ectromelia Virus," <i>Journal of Virology</i> 76(3):1124-1134.	
32	34.	The University of Texas Medical Branch at Galveston. (Date Unknown). "New Drug Reduces Frequency of Genital Herpes Flare-ups," located at < <a href="http://www.utmb.edu/newsroom/01pr_archive/jul_2001/resiquimod.htm">http://www.utmb.edu/newsroom/01pr_archive/jul_2001/resiquimod.htm</a> >, last visited on November 17, 2005, 2 pages.	
32	35.	United States Patent Application No. 09/802,518 filed on March 9, 2001 for Van Nest, 58 pages.	
32	36.	Unknown. (Date Unknown). "Resiquimod (Topical), 3M," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...</a> >, last visited on October 7, 2005, 1 page.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	1/9/06
--------------------	--	-----------------	--------

pa- 1026218